The NRAS, HRAS and KRAS market is expected to reach USD 73 million in 2021 and anticipated to grow at a CAGR of 53.6% during the forecast period 2021-2031

In 2020, an estimated 10 million reported fatalities were attributed to cancer, standing as a significant global cause of mortality. The predominant reason for this high mortality rate often stems from late detection, leading to delayed treatment and subsequently diminishing survival prospects. The COVID-19 pandemic further complicated the landscape of cancer care as healthcare facilities had to make the difficult decision to cancel visits to preserve resources and curb the spread of the virus. As a result, the National Cancer Institute has projected a potential 10,000 preventable deaths in the coming decade due to delays in cancer screening and treatment induced by the pandemic. Globally, the reported cases of cancer in 2020 amounted to approximately 50.5 million, with breast and lung cancers prevailing as the most common types.

The pursuit of cancer therapeutics continues to be a paramount focus within the pharmaceutical industry, owing to the challenges associated with conventional treatments like chemotherapy and radiation therapy. Presently, developers are directing their efforts towards drugs that target specific oncogenic mutations driving disease progression. Notably, previously deemed "undruggable" targets, such as RAS mutations present in 30% of human cancers, have garnered significant attention. These efforts culminated in the USFDA’s approval of LUMAKRAS? (sotorasib) in 2021 for treating metastatic non-small cell lung cancer in patients with KRAS G12C mutations. The efficacy and safety profile of this drug have ignited investigations into its potential application across various solid tumor indications, including colorectal cancer. Multiple entities, encompassing major pharmaceutical companies, are actively engaged in the development of therapies targeting RAS mutations due to the promising prospects, thereby attracting substantial interest from both private and public investors. With numerous candidates progressing to advanced development stages, a robust market expansion is anticipated within this domain.

Report Coverage
? The report examines the KRAS market, focusing on target indication, molecule type, therapy type, administration route, and key geographical regions.
? An analysis is conducted on factors impacting market growth, including drivers, restraints, opportunities, and challenges.
? Evaluation of potential advantages and obstacles within the market is provided, along with insights into the competitive landscape for leading market players.
? Revenue forecasts are made for market segments across five major regions.
? A comprehensive overview of current therapies targeting RAS is presented, detailing their developmental status, molecule types, therapy approaches, targeted diseases, genes, treatment lines, and administration routes. Additionally, it includes information about companies involved in RAS targeting therapy development based on establishment year, employee count, and global presence.
? An extensive analysis of completed, ongoing, and planned clinical trials focusing on RAS targeting therapies is included, evaluating parameters such as trial details, patient demographics, sponsors, objectives, indications, and geographical distribution.
? Competitive analysis focuses on key players in the KRAS market, assessing their portfolio strength, company sizes, and lead molecule development stages.
? Detailed profiles of major players in RAS targeting therapies are provided, encompassing company overview, product portfolio, recent advancements, and future outlook.
? Analysis of over 1,600 peer-reviewed scientific articles published between January 2020 and April 2021 related to RAS targeting therapy research is conducted. This includes trends in publication years, focus areas, molecule types, keywords, and key journals based on article numbers and impact factors.
? Recent partnerships established between stakeholders in RAS targeting therapy development from 2016 to 2021 are described, focusing on partnership models such as R&D agreements, licensing agreements, product development, and clinical trial agreements.
? In-depth analysis of investments made in the KRAS market from 2016 to 2021, including venture capital financing, debt financing, grants/awards, IPOs, and subsequent offerings, is provided.
? Detailed commercialization strategies employed by drug developers engaged in the KRAS market across different therapy development stages - before drug launch, during drug launch, and post-marketing stage - are examined.


Key Market Companies
? Amgen
? GlobeImmune
? Jacobio Pharmaceuticals
? Mirati Therapeutics
? Novartis
? Onconova Therapeutics
? Targovax
? Verastem Oncology